S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
How major US stock indexes fared Friday 9/30/2022
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
How major US stock indexes fared Friday 9/30/2022
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
How major US stock indexes fared Friday 9/30/2022
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
EV Battery Maker Freyr Set For Major Global Expansion
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
Russia accused of 'kidnapping' head of Ukraine nuclear plant
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
MarketBeat: Week in Review 9/26 – 9/30
How major US stock indexes fared Friday 9/30/2022
Can A.I. Launch You into Your Next Trading Frontier? (Ad)pixel
EU chief: New Greece-Bulgaria gas pipeline 'means freedom'
West rejects Putin's claim it sabotaged Baltic gas pipelines
NASDAQ:NYMX

Nymox Pharmaceutical - NYMX Stock Forecast, Price & News

$0.41
+0.05 (+13.71%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.37
$0.42
50-Day Range
$0.33
$0.61
52-Week Range
$0.19
$2.15
Volume
79,792 shs
Average Volume
74,692 shs
Market Capitalization
$37.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NYMX stock logo

About Nymox Pharmaceutical (NASDAQ:NYMX) Stock

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.

Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Stock News Headlines

NYMOX Updates Shareholders
NYMOX Receives Deficiency Letter from NASDAQ
Executives Buy Around $5M Of 4 Penny Stocks
Nymox Announces Closing of $6.4 Million Financing
Nymox Direct Offering
Nymox Announces $5 Million Registered Direct Offering
Nymox Shareholder Update
See More Headlines
Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Company Calendar

Last Earnings
8/15/2022
Today
10/01/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NYMX
Employees
3
Year Founded
N/A

Profitability

Net Income
$-12,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.01) per share

Miscellaneous

Free Float
41,529,000
Market Cap
$37.44 million
Optionable
Optionable
Beta
0.81

Key Executives

  • Dr. Paul Averback DABP (Age 71)
    M.D., Founder, Chairman, CEO & Pres
    Comp: $750k
  • Mr. Randall J. Lanham Esq. (Age 58)
    J.D., Gen. Counsel, Sec., COO & Director
    Comp: $435.29k
  • Ms. Lin Dodd
    QA and Compliance Mang.













NYMX Stock - Frequently Asked Questions

How have NYMX shares performed in 2022?

Nymox Pharmaceutical's stock was trading at $1.30 at the beginning of the year. Since then, NYMX stock has decreased by 68.1% and is now trading at $0.4147.
View the best growth stocks for 2022 here
.

When is Nymox Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our NYMX earnings forecast
.

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) posted its earnings results on Monday, August, 15th. The biopharmaceutical company reported $0.01 EPS for the quarter.

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $0.41.

How much money does Nymox Pharmaceutical make?

Nymox Pharmaceutical (NASDAQ:NYMX) has a market capitalization of $37.44 million. The biopharmaceutical company earns $-12,540,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The official website for the company is www.nymox.com. The biopharmaceutical company can be reached via phone at (800) 936-9669, via email at info@nymox.com, or via fax at 514-332-2227.

This page (NASDAQ:NYMX) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.